Published in J Natl Cancer Inst on June 07, 2000
Gatekeeper for endometrium: the PTEN tumor suppressor gene. J Natl Cancer Inst (2000) 15.41
PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 2.81
Pten, a protean tumor suppressor. Am J Pathol (2001) 2.42
Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res (2009) 2.32
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 2.27
PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol (2002) 2.16
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet (2008) 1.96
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet (2001) 1.81
Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch (2004) 1.80
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol (2011) 1.80
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol (2009) 1.78
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer (2006) 1.61
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma. Cancer Prev Res (Phila) (2010) 1.60
Role of progesterone in endometrial cancer. Semin Reprod Med (2010) 1.53
Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet (2003) 1.41
Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol (2010) 1.32
Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol (2012) 1.32
DNA methylation in endometrial cancer. Epigenetics (2010) 1.32
Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol (2005) 1.26
Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol (2002) 1.25
Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab (2011) 1.25
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol (2012) 1.21
Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet (2011) 1.19
Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol (2002) 1.19
Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet (2001) 1.17
Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol (2010) 1.17
Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer (2002) 1.16
Challenges in the management of a patient with Cowden syndrome: case report and literature review. Hered Cancer Clin Pract (2012) 1.16
Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res (2010) 1.16
Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer (2012) 1.14
An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther (2015) 1.14
Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci U S A (2010) 1.13
DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Am J Pathol (2002) 1.12
Diagnosis of premalignant endometrial disease. J Clin Pathol (2002) 1.12
A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One (2011) 1.12
Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol (2014) 1.11
A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer (2006) 1.10
EIN and WHO94. J Clin Pathol (2005) 1.08
Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. J Pathol (2013) 1.06
PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res (2008) 1.05
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res (2009) 1.04
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther (2013) 1.04
The genomics and genetics of endometrial cancer. Adv Genomics Genet (2012) 1.03
Clinicopathological significance of PTEN and bcl2 expressions in oral squamous cell carcinoma. Int J Clin Exp Pathol (2012) 1.02
Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial. Br J Cancer (2012) 1.01
Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch (2004) 1.00
Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function. Hum Mol Genet (2009) 1.00
Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status. Med Sci Monit Basic Res (2014) 0.98
Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet Gynecol Int (2010) 0.97
The effect Akt2 deletion on tumor development in Pten(+/-) mice. Oncogene (2011) 0.96
p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. Neoplasia (2008) 0.96
The p85beta regulatory subunit of PI3K serves as a substrate for PTEN protein phosphatase activity during insulin mediated signaling. Biochem Biophys Res Commun (2010) 0.96
Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark (2010) 0.95
Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther (2012) 0.95
Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells. Cancer Res (2013) 0.95
Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol (2012) 0.95
Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment. Gynecol Oncol (2010) 0.94
PTEN-mediated AKT activation contributes to the reduced apoptosis among Indian oral squamous cell carcinoma patients. J Cancer Res Clin Oncol (2011) 0.93
Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid (2011) 0.92
Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res (2006) 0.92
Origin of ovarian cancer: molecular profiling. J Obstet Gynaecol India (2013) 0.91
Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. Mol Cancer Ther (2013) 0.91
The PTEN/NRF2 axis promotes human carcinogenesis. Antioxid Redox Signal (2014) 0.90
Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Res (2013) 0.90
Genetics of endometrial cancers. Obstet Gynecol Int (2010) 0.90
Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography. Neoplasia (2001) 0.89
Nuclear PTEN levels and G2 progression in melanoma cells. Melanoma Res (2009) 0.89
Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastroenterol (2004) 0.89
Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics. Anemia (2012) 0.88
Precursors of endometrial and ovarian carcinoma. Virchows Arch (2009) 0.88
PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol (2003) 0.87
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol (2012) 0.87
Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol (2009) 0.87
Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer. Oncol Lett (2013) 0.87
Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol (2013) 0.86
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget (2015) 0.86
Squamous morules are functionally inert elements of premalignant endometrial neoplasia. Mod Pathol (2008) 0.86
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.86
Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagn Pathol (2009) 0.86
Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues. Cancer Res (2014) 0.86
Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. J Cancer Res Clin Oncol (2007) 0.86
Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases. Br J Cancer (2004) 0.86
Visual gene-network analysis reveals the cancer gene co-expression in human endometrial cancer. BMC Genomics (2014) 0.86
JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer. Oncotarget (2016) 0.86
Adenovirus mediated homozygous endometrial epithelial Pten deletion results in aggressive endometrial carcinoma. Exp Cell Res (2011) 0.85
Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice. Cancer Biol Ther (2010) 0.85
Cowden syndrome: mucocutaneous lesions as precursors of internal malignancy. Oral Maxillofac Surg (2014) 0.85
Treatment for advanced and recurrent endometrial carcinoma: combined modalities. Oncologist (2010) 0.84
Long Non-Coding RNAs in Endometrial Carcinoma. Int J Mol Sci (2015) 0.84
Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms. Cancer (2009) 0.84
Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. Int J Clin Oncol (2006) 0.84
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies. Front Oncol (2013) 0.84
Reproducibility determination of WHO classification of endometrial hyperplasia/well differentiated adenocarcinoma and comparison with computerized morphometric data in curettage specimens in Iran. Diagn Pathol (2009) 0.83
Molecular and phenotypic abnormalities in individuals with germline heterozygous PTEN mutations and autism. Mol Psychiatry (2014) 0.83
Gatekeeper for endometrium: the PTEN tumor suppressor gene. J Natl Cancer Inst (2000) 15.41
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell (1992) 6.32
Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature (1995) 6.16
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 5.81
Is secondary haemorrhage after tonsillectomy in adults an infective condition? Objective measures of infection in a prospective cohort. Clin Otolaryngol (2007) 5.45
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet (1998) 4.72
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet (2001) 4.71
Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J (1992) 4.69
Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet (1997) 4.39
Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev (1993) 4.14
Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet (2005) 4.14
Patient empowerment. Results of a randomized controlled trial. Diabetes Care (1995) 3.97
Complete transformation by adenovirus 2 requires both E1A proteins. Cell (1984) 3.80
Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet (2001) 3.58
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev (1994) 3.47
E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol (1996) 3.40
Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell (1990) 3.37
E2f3 is critical for normal cellular proliferation. Genes Dev (2000) 3.26
Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2000) 3.23
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet (1999) 3.22
The Diabetes Empowerment Scale: a measure of psychosocial self-efficacy. Diabetes Care (2000) 2.91
Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol (1992) 2.79
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol (1999) 2.79
Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet (2001) 2.77
Heterogeneity of mitotic activity in breast cancer. Histopathology (1996) 2.77
Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell (1999) 2.71
The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc Natl Acad Sci U S A (2001) 2.65
5'-Guanylylimidodiphosphate, a potent activator of adenylate cyclase systems in eukaryotic cells. Proc Natl Acad Sci U S A (1974) 2.63
Pneumococcal bacteraemia in two immunocompetent adults with otitis media and bronchitis. Lancet (1990) 2.59
Structural organization and expression of the mouse estrogen receptor. Mol Endocrinol (1987) 2.54
Hypoglycemia in hospitalized patients. Causes and outcomes. N Engl J Med (1986) 2.44
Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract (2008) 2.39
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A (2001) 2.38
The inhibition of plant and animal adenosine 3':5'-cyclic monophosphate phosphodiesterases by a cell-division-promoting substance from tissues of higher plant species. Proc Natl Acad Sci U S A (1972) 2.36
E2F activity is regulated by cell cycle-dependent changes in subcellular localization. Mol Cell Biol (1997) 2.33
Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet (2004) 2.29
Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 2.27
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol (2000) 2.23
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
E2F4 is essential for normal erythrocyte maturation and neonatal viability. Mol Cell (2000) 2.21
Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol (2001) 2.20
E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. Genes Dev (2001) 2.16
Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet (2000) 2.15
Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA (1999) 2.14
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet (1994) 2.14
Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A (1999) 2.10
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet (1999) 2.08
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res (1997) 2.06
Role of adenine and guanine nucleotides in the activity and response of adenylate cyclase systems to hormones: evidence for multisite transition states. Adv Cyclic Nucleotide Res (1975) 2.06
Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet (2000) 2.05
Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol (2000) 2.05
Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J Lipid Res (2001) 2.02
Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet (1996) 2.01
PTEN mutations in gliomas and glioneuronal tumors. Oncogene (1998) 2.01
Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem (1996) 2.01
The value of morphometry to classic prognosticators in breast cancer. Cancer (1985) 2.00
In vivo association of E2F and DP family proteins. Mol Cell Biol (1995) 1.99
E2F-6, a member of the E2F family that can behave as a transcriptional repressor. Proc Natl Acad Sci U S A (1998) 1.99
Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 1.97
Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet (2004) 1.96
Relationships between vascularization and proliferation in invasive breast cancer. J Pathol (1999) 1.90
PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet (2001) 1.87
Molecular characterisation of a common SDHB deletion in paraganglioma patients. J Med Genet (2007) 1.86
PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res (1999) 1.85
Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet (2000) 1.84
Molecular identification of latent precancers in histologically normal endometrium. Cancer Res (2001) 1.84
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet (2001) 1.81
Evidence for interdependent action of glucagon and nucleotides on the hepatic adenylate cyclase system. J Biol Chem (1974) 1.80
Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res (2000) 1.78
Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest (1995) 1.75
Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. J Clin Pathol (1987) 1.71
Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. Dev Biol (2001) 1.71
PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet (2001) 1.69
Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet (1995) 1.68
The pRB-related protein p107 contains two growth suppression domains: independent interactions with E2F and cyclin/cdk complexes. EMBO J (1995) 1.67
Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J (1994) 1.67
Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet (2001) 1.66
Carney complex, Peutz-Jeghers syndrome, Cowden disease, and Bannayan-Zonana syndrome share cutaneous and endocrine manifestations, but not genetic loci. J Clin Endocrinol Metab (1998) 1.63
Germline SDHD mutation in familial phaeochromocytoma. Lancet (2001) 1.62
Proliferation markers in tumours: interpretation and clinical value. J Clin Pathol (1998) 1.62
Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol (1998) 1.62
Regulation of the insulin-like developmental pathway of Caenorhabditis elegans by a homolog of the PTEN tumor suppressor gene. Proc Natl Acad Sci U S A (1999) 1.62
Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer (2012) 1.61
Specific regulation of E2F family members by cyclin-dependent kinases. Mol Cell Biol (1997) 1.61
Microsomal triglyceride transfer protein. Biochim Biophys Acta (1997) 1.60